Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554408 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
A Phase 1 study of Human Immunodeficiency Virus, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT03554408 is a Phase 1 study of Human Immunodeficiency Virus that has completed, run by Rockefeller University. The registered enrollment target is 77 participants, below the 182-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03554408, a Phase 1 study of Human Immunodeficiency Virus, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.
Conditions Studied
Interventions
- DRUG 3BNC117-LS
- DRUG 10-1074-LS
Study Locations (1)
New York
- The Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03554408
The ClinicalTrials.gov registry entry for NCT03554408 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (58% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which 3BNC117-LS is the first listed.
NCT03554408 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03554408 about?
NCT03554408 is a clinical study titled "First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS". This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.
What is the current status of trial NCT03554408?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2018-06-20. Estimated completion is 2021-02-04.
What conditions does trial NCT03554408 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT03554408?
The interventions under investigation include: 3BNC117-LS (DRUG), 10-1074-LS (DRUG).
Who is sponsoring clinical trial NCT03554408?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03554408 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
RECRUITING · Phase 1
-
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
COMPLETED · Phase 1
-
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
COMPLETED · Phase 1
-
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
COMPLETED · Phase 1
-
First in Human Study of TLC-ART 101 (ACTU 2001)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.